NCT06254183CompletedPhase 4
Effect of Gabapentin on Kidney Function Following Laparoscopic Sleeve Gastrectomy (LSG)
Clinical Study Evaluating the Effect of Gabapentin on Kidney Function Following Laparoscopic Sleeve Gastrectomy (LSG) for Morbid Obese Patients
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
This study evaluated the effect of a single preoperative dose of gabapentin on renal stress and kidney function following laparoscopic sleeve gastrectomy in adults with severe obesity. Sixty participants undergoing laparoscopic sleeve gastrectomy were randomized in a 1:1 ratio to surgery without preoperative gabapentin or surgery after a single 1200-mg oral dose of gabapentin. An additional 30 non-operative participants with severe obesity served as a non-randomized external reference cohort. Renal assessment included conventional kidney function markers and biomarkers, including Dickkopf-3 (DKK3) and neutrophil gelatinase-associated lipocalin (NGAL). The prespecified primary endpoint was urinary DKK3 concentration at 24 hours postoperatively.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 22 Jan 2024
- Start date
- 1 Dec 2024
- Primary completion date
- 1 May 2025
- Lead sponsor
- Tanta University
- Diseases
- Obesity
- NCT number
- NCT06254183
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 90
- From 1 Dec 2024 to the primary completion date, 1 May 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Advanced cancer receiving active treatment.
- Use of medications that could interfere with the assessed study parameter
Other illness
- End-stage renal, hepatic, or cardiopulmonary disease.
- Untreated schizophrenia or cognitive impairment.
- Use of psychiatric medications, as specified in the study protocol.
- Chronic use of gabapentin or known hypersensitivity to gabapentin.
Other
- Active substance abuse.
- Pregnancy or breastfeeding.
Who the study is looking for
- Age: 18-65 years old.
- Participants with severe obesity (BMI ≥40 kg/m², without comorbidities or BMI ≥35 kg/m², in the presence of obesity-related comorbidities).
- Preserved kidney function at baseline.
- For the randomized surgical cohort (Groups II and III), participants with severe obesity scheduled to undergo laparoscopic sleeve gastrectomy.
- For the non-randomized external reference cohort (Group I), participants with severe obesity who did not undergo laparoscopic sleeve gastrectomy during the study period or receive the study intervention.
- Both sexes.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mansoura University Hospitals Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
| Tanta University Hospitals Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.